Ragistomig
- Generic Name
- Ragistomig
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04762641
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸USC, LA, California, United States
🇺🇸UCLA, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath